trends in PHARMACOLOGICAL SCIENCES

including TOXICOLOGICAL SCIENCES

Author Index

Subject Index

Books Reviewed Index

1997

Vol 18
Issues 1–12

ISSN 0165 6147

Trends in Pharmacological Sciences

Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 1LA
Tel: +44 1223 315961
Fax: +44 1223 464430
+44 1223 321410
E-mail: TIPS@elsevier.co.uk

Advisory Editorial Board

P. M. Beart, Monash University, Melbourne, Australia
N. J. M. Birdsall, National Institute of Medical Research, London, UK
N. G. Bowery, University of Birmingham, Birmingham, UK
J. N. Crawley, National Institute of Mental Health, Bethesda, MD, USA
A. C. Cuello, McGill University, Montréal, Canada
A. Dray, Astra, Montréal, Canada
J. R. Fozard, Novartis, Basel, Switzerland
B. B. Fredholm, Karolinska Institute, Stockholm, Sweden
T. Godfraind, Université Catholique de Louvain, Brussels, Belgium
M. Lazdunski, Université de Nice, Valbonne, France
P. Leff, Astra, Loughborough, UK
L. Limbird, Vanderbilt University, Nashville, TN, USA
J. Meldolesi, Instituto H. San Raffaele, Milan, Italy
M. Otsuka, Tokyo Medical & Dental University, Tokyo, Japan
C. P. Page, King's College, London, UK
U. Quast, University of Tübingen, Germany
M. M. Reidenberg, Cornell Medical Center, New York, NY, USA
R. Ruffolo, Jr, SmithKline Beecham, King of Prussia, PA, USA
C. D. Strader, Schering-Plough Research Institute, Kenilworth, NJ, USA
H. Timmerman, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Z. G. Wang, Institute of Basic Medical Sciences, Beijing, China

Editor **Rachel Babbedge**

Assistant Editor **Annette Mead**

Editorial Administrator **Claire Robson**

Publisher **Peter Desmond**

Copyright © 1998 Elsevier Science Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

Author Index

BR Book Review
L Letter
SR Software Review

A

Aarbakke, J., Janka-Shaub, G. and Elion, G. B., Thiopurine biology and pharmacology 3
Abbott, N. J., *see* Connolly, G. P. 413
Abbracchio, M. P., *see* Fredholm, B. 79
Adcock, I. M., *see* Barnes, P. J. 46
Agrawal, S., *see* Akhtar, S. 12
Akhtar, S. and Agrawal, S., *In vivo* studies with antisense oligonucleotides 12
Alderton, W. and Knowles, R., Nitric Oxide Synthase: Characterization and Functional Analysis (BR) 100
Anderson, C. M. and Parkinson, F. E., Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides 387
Anderson, G. P., Bcl-2 related proteins, apoptosis and disease 51
Arribas, S., *see* McGrath, J. C. 181
Azzi, M., *see* Betancur, C. 372

B

Babbedge, R., Bristol–Myers Squibb Unrestricted Biomedical Research Grants Programme 151
Babbedge, R., Royal Society Muller Award 306
Bagetta, G., *see* Nicotera, P. 189
Bailey, D., *see* Williamson, A. R. 303
Barlow, R., Tutorials for the Biomedical Sciences (BR) 63
Barnard, E. A., Ionotropic glutamate receptors: new types and new concepts 141
Barnes, P. J. and Adcock, I. M., NF-κB: a pivotal role in asthma and a new target for therapy 46
Bastianetto, S. and Quirion, R., Any facts behind the DHEA hype? 447
Battistini, B., The Institute of Pharmacology of Sherbrooke: a first in Canada 65
Belkin, M., *see* Solberg, Y. 183
Bellchambers, C. E., *see* Christie, M. J. 134
Bergsma, D. J., *see* Stadel, J. M. 430
Bernardi, G., *see* Mercuri, N. B. 232
Betancur, C., Azzi, M. and Rostene, W., Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy 372
Binaschi, M., *see* Capranico, G. 323
Boeynaems, J-M., *see* Communi, D. 83
Bonci, A., *see* Mercuri, N. B. 232
Bond, R. A., *see* Milligan, G. 468
Borgnetto, M. E., *see* Capranico, G. 323
Botting, R. and Vane, J., Readdressing relative selectivities of NSAIDs (L) 312
Boucher, R. C., *see* Harden, T. K. 43
Bowery, N. G., Metabotropic $GABA_B$ receptors cloned at last 103
Brink, C., *see* Gorenne, I. (L) 148
Bristow, L. J., Kramer, M. S., Kulagowski, J., Patel, S. and Seabrook, G., Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist 186
Brune, B., *see* Nicotera, P. 189
Buhr, A., *see* Sigel, E. 425
Burnstock, G., *see* Fredholm, B. 79
Busch, A. E. and Suessbrich, H., Role of the I_{sk} protein in the I_{minK} channel complex 26

C

Capra, V., *see* Rovati, G. E. 148
Capranico, G., Binaschi, M., Borgnetto, M. E., Zunino, F. and Palumbo, M., A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons 323
Capranico, G., The Camptothecins: from Discovery to the Patient (BR) 445
Carruba, M. O., *see* Nisoli, E. (L) 257
Chang, D. J., *see* Eglen, R. M. 104
Christie, M. J., Williams, J. T., Osborne, P. B. and Bellchambers, C. E., Where is the locus in opioid withdrawal? 134
Clarke, D. E., Drug discovery: some directional pointers 19
Clementi, E. and Meldolesi, J., The cross-talk between nitric oxide and Ca^{2+}: a story with a complex past and a promising future 266
Clifton, P. G. and Lee, M. D., Fluoxetine hypophagia (L) 191
Coleman, R., Coleman replies (L) 150
Communi, D. and Boeynaems, J-M., Receptors responsive to extracellular pyrimidine nucleotides 83
Connolly, G. P., Abbott, N. J., Demaine, C. and Duley, J. A., Investigation of receptors responsive to pyrimidines 413
Contreras, E., *see* Rodriguez, R. 314
Cooper, N., *see* Teixeira, M. M. 164
Curtis, M. J. and Pabla, R., Nitric oxide supplementation or synthesis block – which is the better approach to treatment of heart disease? 239
Curzon, G., Leigh Gibson, E. and Oluyomi, A. O., Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability 21
Curzon, G., Oluyomi, A. O. and Gibson, E. L., Curzon *et al.* reply (L) 191

D

Daly, C. J., *see* McGrath, J. C. 181
de Cupis, A. and Favoni, R. E., Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens 245
De Ponti, F., Pharmacological criteria for the detection of β_3-adrenoceptors (L) 52
Demaine, C., *see* Connolly, G. P. 413
di Chiara, G., Cortical and limbic dopamine (on opiate addiction): do not mix before use! (L) 77
Doble, A., *see* Louvel, E. 196
Donaldson, L., Hanley, M. R. and Villablanca, A., Inducible receptors 171
Douglas, S. A., Clinical development of endothelin receptor antagonists 408
Dubyak, G. R., *see* Fredholm, B. 79
Duley, J. A., *see* Connolly, G. P. 413
Dykes, C. W., *see* Williamson, A. R. 303

E

Eder, J., Tumour necrosis factor α and interleukin I signalling: do MAPKK kinases connect it all? 319
Edwardson, M., *see* Koenig, J. 276
Eglen, R. M., Jasper, J. R., Chang, D. J. and Martin, G. R., The 5-HT_7 receptor: orphan found 104
Elion, G. B., *see* Aarbakke, J. 3
Erjefält, J. S., *see* Persson, C. G. A. 117
Erjefält, J. S., *see* Persson, C. G. A. 465
Ertel, E. A., *see* Ertel, S. I. 37
Ertel, S. I. and Ertel, E. A., Low-voltage-activated T-type Ca^{2+} channels 37

F

Fabisch, H., *see* Zernig, G. 229
Fabisch, K., *see* Zernig, G. 229
Favoni, R., Estrogens, Progestins and their Antagonists (Vols 1 and 2) (Vol. 1 Health issues) (Vol. 2 Functions and Mechanisms of Action) (BR) 182
Favoni, R. E., *see* de Cupis, A. 245
Feltz, A., *see* Nooney, J. M. 363
Ferguson, D. R., Pharmacology: A Clinical Core Text for Integrated Curricula with Self-Assessment (BR) 63
Fredholm, B., Abbracchio, M. P., Burnstock, G., Dubyak, G. R. and Harden, T. K., Towards a revised nomenclature for adenosine and P2 receptors 79
Frölich, J. C., A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes 30
Frölich, J. C., Frölich replies to Griswold *et al.* (L) 312
Frölich, J. C., Frölich replies to Botting and Vane (L) 313

G

Galione, A., *see* Genazzani, A. A. 108
Genazzani, A. A. and Galione, A., A Ca^{2+} release mechanism gated by the novel pyridine nucleotide, NAADP 108
Gibson, E. L., *see* Curzon, G. (L) 191
Gillies, G. E., Somatostatin: the neuroendocrine story 87
Glossman, H., *see* Moebius, F. F. 67
Gorenne, I., Norel, X. and Brink, C., Gorenne *et al.* reply (L) 148
Grissmer, S., Potassium channels still hot 347
Gristwood, R. W., *see* Teixeira, M. M. 164
Griswold, D. E., Ruffolo, R. R., Poste, G. and Torphy, T. J., Reclassification of NSAIDs (L) 311
Grundemar, L. and Ny, L., Pitfalls using metalloporphyrins in carbon monoxide research 193

H

Hagan, J. J., Middlemiss, D. N., Sharpe, P. C. and Poste, G. H., Parkinson's disease: prospects for improved therapy 156
Hagan, J. J., Middlemiss, D. N., Sharpe, P. C. and Poste, G. H., Hagan *et al.* reply (L) 310
Handy, R. L. C., *see* Moore, P. K. 204
Hanley, M. R., *see* Donaldson, L. 171
Harden, T. K., Lazarowski, E. R. and Boucher, R. C., Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity 43
Harden , T. K ., *see* Fredholm, B. 79
Hellewell, P. G., *see* Teixeira, M. M. 164
Henderson, G., Hans Walter Kosterlitz 1
Henderson, G. and McKnight, A. T., The orphan opioid receptor and its endogenous ligand – nociceptin/orphanin FQ 293
Hernandez, T. D., Preventing post-traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis 59
Hescheler, J., *see* Schneider, T. 8
Hobbs, A. J., Soluble guanylate cyclase: the forgotten sibling 484
Hollingsworth, M., *see* Hughes, I. 111
Hughes, I., Hollingsworth, M., Jones, S. J. and Markham, T., Knowledge and skills needs of pharmacology graduates in first employment: how do pharmacology courses measure up? 111
Hugon, J., *see* Louvel, E. 196
Huizinga, J. D., Thuneberg, L., Vanderwinden, J-M. and Rumessen, J., Interstitial cells of Cajal as targets for pharmacological intervention in gastrointestinal motor disorders 393

I

Igelmund, P., *see* Schneider, T. 8

J

Jack, D., The interaction of salmaterol with the β_2-adrenoceptor protein (L) 149
Janka-Shaub, G., *see* Aarbakke, J. 3
Jasper, J. R., *see* Eglen, R. M. 104
Jenner, P., *see* Richardson, P. J. 338
Johnson, S. R. and Knox, A. J., Synthetic functions of airway smooth muscle in asthma 288
Jones, S. J., *see* Hughes, I. 111

K

Kase, H., *see* Richardson, P. J. 338
Kato, A., *see* Sagot, Y. 330
Kaumann, A. J., Four β-adrenoceptor subtypes in the mammalian heart 70
Kaumann, A. J., Four β-adrenoceptor subtypes in the mammalian heart 181
Kaumann, A. J., *see* Molenaar, P. (L) 258
Kenakin, T., Agonist-specific receptor conformations 416
Kenakin, T., Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry 456
Kennedy, C., Autonomic Pharmacology (BR) 259
Kennedy, C., Todorov, L. D., Mihaylova-Todorova, S. and Sneddon, P., Release of soluble nucleotidases: a novel mechanism for neurotransmitter inactivation? 263
Klein, W., *see* Stoschitzsky, K. 306
Knowles, R., *see* Alderton, W. (BR) 100
Knox, A. J., *see* Johnson, S. R. 288
Kobilka, B. K., *see* MacDonald, E. 211
Koenig, J. and Edwardson, M., Endocytosis and recycling of G protein-coupled receptors 276
Kohl, N., *see* Omer, C. 437
Korsgren, M., *see* Persson, C. G. A. 465
Kramer, M. S., *see* Bristow, L. J. 186
Kulagowski, J., *see* Bristow, L. J. 186
Kutalek, S. P., *see* Pelleg, A. 236

L

Lambert, J. J., *see* Peters, J. A. 454
Lambert, R. C., *see* Nooney, J. M. 363
Langer, S. Z., 25 Years since the discovery of presynaptic receptors: present knowledge and future perspectives 95
Laurence, D. R., What is pharmacology? A discussion 153
Law, C., *see* Leff, P. 355
Lazarowski, E. R., *see* Harden, T. K. 43
Lee, M. D., *see* Clifton, P. G. (L) 191
Leff, P., Scaramellini, C., Law, C. and McKechnie, K., A three-state receptor model of agonist action 355
Leigh Gibson, E., *see* Curzon, G. 21
Lindner, W., *see* Stoschitzsky, K. 306
Lloyd, G. K., *see* Williams, M. (L) 307
Lopez-Martinez, E., *see* Rodriguez, R. 314
Louvel, E., Hugon, J. and Doble, A., Therapeutic advances in amyotrophic lateral sclerosis 196

M

MacDonald, E., Kobilka, B. K. and Scheinin, M., Gene targeting – homing in on α_2-adrenoceptor-subtype function 211
Maggi, C. and Schwartz, T., The dual nature of the tachykinin NK_1 receptor 351
Markham, T., *see* Hughes, I. 111
Martin, G. R., *see* Eglen, R. M. 104
Maser, E., Stress, hormonal changes, alcohol, food constituents and drugs: factors that advance the incidence of tobacco smoke-related cancer? 270
McGrath, J. C., Arribas, S. and Daly, C. J., Fluorescent ligands for the study of receptors 181
McKechnie, K., *see* Leff, P. 355
McKnight, A. T., *see* Henderson, G. 293
Meldolesi, J., *see* Clementi, E. 266
Mercuri, N. B., Bonci, A. and Bernardi, G., Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs 232
Methods in Neurosciences (BR) 100
Middlemiss, D. N., *see* Hagan, J. J. 156
Middlemiss, D. N., *see* Hagan, J. J. (L) 310
Mihaylova-Todorova, S., *see* Kennedy, C. 263
Milligan, G. and Bond, R. A., Inverse agonism and the regulation of receptor number 468
Moebius, F. F., Glossman, H. and Streissnig, J., The mystery of sigma receptors: new family members reveal a role in cholesterol synthesis 67
Molenaar, P. and Kaumann, A. J., On criteria for functional β_3-adrenoceptors (L) 258
Mombouli, J-V. and Vanhoutte, P. M., Endothelium-derived hyperpolarizing factor(s): updating the unknown 252
Moore, P. K. and Handy, R. L. C., Selective inhibitors of neuronal nitric oxide synthase – is no NOS really good NOS for the nervous system? 204

N

Nagy, I., *see* Urban, L. 223
Nicosia, S., *see* Rovati, G. E. 148
Nicotera, P., Brune, B. and Bagetta, G., Nitric oxide: inducer or suppressor of apoptosis? 189
Nisoli, E. and Carruba, M. O., Pharmacological properties of β_3-adrenoceptors (L) 257
Nooney, J. M., Lambert, R. C. and Feltz, A., Identifying neuronal non-L Ca^{2+} channels – more than stamp collecting? 363
Norel, X., *see* Gorenne, I. (L) 148
Ny, L., *see* Grundemar, L. 193

O

Oluyomi, A. O., *see* Curzon, G. 21
Oluyomi, A. O., *see* Curzon, G. (L) 191
Omer, C. and Kohl, N., CA_1A_2X-competitive inhibitors of farnesyltransferase as anti-cancer agents 437
Osborne, P. B., *see* Christie, M. J. 134

P

Pabla, R., *see* Curtis, M. J. 239
Palumbo, M., *see* Capranico, G. 323
Parkinson, F. E., *see* Anderson, C. M. 387
Patel, S., *see* Bristow, L. J. 186
Peers, C., Oxygen-sensitive ion channels 405
Pelleg, A. and Kutalek, S. P., Adenosine suppresses ventricular automaticity in the mammalian heart 236
Perretti, M., Endogenous mediators that inhibit the leucocyte–endothelium interaction 418
Persson, C. G. A. and Erjefält, J. S., Eosinophil lysis and free granules: an *in vivo* paradigm for cell activation and drug development 117
Persson, C. G. A., Erjefält, J. S., Korsgren, M. and Sundler, F., The mouse trap 465
Peters, J. A. and Lambert, J. J., Anaesthetics in a bind? 454
Pietri-Rouxel, F., *see* Strosberg, A. D. (L) 52
Poste, G., *see* Griswold, D. E. (L) 311
Poste, G. H., *see* Hagan, J. J. 156
Poste, G. H., *see* Hagan, J. J. (L) 310

Q

Quirion, R., *see* Bastianetto, S. 447

R

Rees, S. A, *see* Wright, A. R. 224
Rees, S., *see* Wright, A. 345

Richardson, P. J., Kase, H. and Jenner, P., Adenosine A_{2A} receptor antagonists as new agents for the treatment of Parkinson's disease 338
Robertson, B., The real life of voltage-gated K^+ channels: more than model behaviour 474
Rodriguez, R., Vidrio, H., Lopez-Martinez, E., Contreras, E. and Valenzuela, F., Changing the countenance of pharmacology courses in medical schools 314
Romanos, M., *see* Williamson, A. R. 303
Rostene, W., *see* Betancur, C. 372
Rovati, G. E., Capra, V. and Nicosia, S., More on the classification of cysteinyl leukotriene receptors 148
Ruffolo, R. R., *see* Griswold, D. E. (L) 311
Rumessen, J., *see* Huizinga, J. D. 393

S

Sagot, Y., Vejsada, R. and Kato, A. Clinical and molecular aspects of motoneurone diseases: animal models, neurotrophic factors and Bcl-2 oncoprotein 330
Saxena, P., Pharmacology of Vascular Smooth Muscle (BR) 100
Scaramellini, C., *see* Leff, P. 355
Scheinin, M., *see* MacDonald, E. 211
Schneider, T., Igelmund, P. and Hescheler, J., G protein interaction with K^+ and Ca^{2+} channels 8
Schwartz, T., *see* Maggi, C. 351
Seabrook, G., *see* Bristow, L. J. 186
Sharpe, P. C., *see* Hagan, J. J. 156
Sharpe, P. C, *see* Hagan, J. J. (L) 310
Sigel, E. and Buhr, A., The benzodiazepine binding site of $GABA_A$ receptors 425
Simonato, M., Simonato replies (L) 78
Smith, G. B., The GABA Receptors (2nd edn) (BR) 260
Sneddon, P., *see* Kennedy, C. 263
Solberg, Y. and Belkin, M., The role of excitotoxicity in organophosphorus nerve agent poisoning of the CNS 183
Spanagel, R. and Zieglgansberger, W., Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes 54
Stadel, J M., Wilson, S. and Bergsma, D. J., Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery 430
Stoschitzsky, K., Klein, W. and Lindner, W., Time to reassess chiral aspects of β-adrenoceptor antagonists 306
Strange, P. G., Drugs and the Brain (BR) 35
Streissnig, J., *see* Moebius, F. F. 67
Strosberg, A. D. and Pietri-Rouxel, F., Strosberg and Pietri-Rouxel reply (L) 52
Strosberg, A., Receptor Signal Transduction Protocols (BR) 446
Strosberg, A. D., Association of β_3-adrenoceptor polymorphism with obesity and diabetes: current status 449
Suessbrich, H., *see* Busch, A. E. 26
Sundler, F., *see* Persson, C. G. A. 465

T

Teixeira, M. M., Gristwood, R. W., Cooper, N. and Hellewell, P. G., Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? 164
Thuneberg, L., *see* Huizinga, J. D. 393
Timmerman, H., Drug Prototypes and their Exploitation (BR) 259
Todorov, L. D., *see* Kennedy, C. 263
Torphy, T. J., *see* Griswold, D. E. (L) 311
Tuček, S., Is the R and R* dichotomy real? 414

U

Urban, L. and Nagy, I., Is there a nociceptive carousel? 223

V

Valenzuela, F., *see* Rodriguez, R. 314
Vanderwinden, J-M., *see* Huizinga, J. D. 393
Vane, J., *see* Botting, R. (L) 312
Vanhoutte, P. M., *see* Mombouli, J-V. 252
Vejsada, R., *see* Sagot, Y. 330
Vellucci, S. V., Autonomic–Endocrine Interactions (BR) 301
Vidrio, H., *see* Rodriguez, R. 314
Villablanca, A., *see* Donaldson, L. 171

W

Williams, J. T., *see* Christie, M. J. 134
Williams, M., Wright, S. and Lloyd, G. K., Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists (L) 307
Williamson, A. R., Dykes, C. W., Romanos, M. and Bailey, D., Human Genome Project Europe 303
Wilson, S., *see* Stadel, J. M. 430
Wright, A. R. and Rees, S. A, Targeting ischaemia – cell swelling and drug efficacy 224
Wright, S., *see* Williams, M. (L) 307

Y

Yakel, J. L., Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription 124

Z

Zernig, G., Fabisch, K. and Fabisch, H., Pharmacotherapy of alcohol dependence 229
Zieglgansberger, W., *see* Spanagel, R. 54
Zunino, F., *see* Capranico, G. 323

Subject Index

compiled by Laurence Errington

A
A currents in brain, voltage-gated K^+ channels and 480
Absence epilepsy, $GABA_B$ receptor ligands 103
ABT-431 308 (L)
Acamprosate 54–56, 57–58, 229–231
Acetylcholine receptor agonists in Parkinson's disease, nicotinic 308 (L)
Acetylcholine receptor antagonists in Parkinson's disease 340, 341–342
Acromegaly 92, 93, 94
ACTH (corticotrophin), calcineurin and 131
ACTH-releasing hormone, *see* Corticotrophin-releasing hormone
Action potentials, GI motility disorders and 402
Activator protein-1, TNF-α/IL-1 and 319–320
Addiction, drug
  alcohol, *see* Alcohol
  opiate 77–78 (L)
  Unit for Research on 1 (O)
Adenine nucleotides, release/metabolism/interconversion 43–50
Adenomas, pituitary 93
Adenosine
  cardiac effects 236–238
  leukocyte–endothelial effects 418–420
Adenosine receptor(s) (A; P1) 79, 338–344
  A_1, induction in inflammation 174, 175
  A_{2A} antagonists, in Parkinson's disease 309, 338–344
  nomenclature 78, 79
Adenylate cyclase
  β_3-adrenoceptors and 452, 453
  $GABA_B$ receptors and 103
  5-HT_7 receptors and 104
Adhesion molecules, airway inflammation/asthma and 289–290, 291
  NF-κB and 48, 49
ADP, release/metabolism/conversion to ATP 43–50
ADP ribose, cyclic 108–110
  ryanodine receptor-mediated Ca^{2+} release and 267–268
ADP ribose cyclase 108–110
Adrenal glomerulosa cells, aldosterone secretion involving T-type Ca^{2+} channels 41
  see also Hypothalamic–pituitary–adrenocortical axis
α_{1B}-Adrenoceptor(s), constitutively active mutant 472, 473
α_2-Adrenoceptor(s) 211–219
  agonists 214
    opioid withdrawal and 138
    therapeutic uses 218–219
  antagonists 214
    of presynaptic receptors 98
    therapeutic uses 219
  phylogenetic tree 213
  subtypes 211–219
  binding characteristics 213–214
  molecular biology 212–213
  tissue distribution 214–215
β-Adrenoceptor antagonists (in general), harmful effects of d-enantiomers 306–307
β_1-Adrenoceptor(s), cardiac 70–71
  agonists and antagonists 71
β_2-Adrenoceptor(s) 471–472
  cardiac 70–71
    agonists and antagonists 71
  constitutively active mutant 471–472, 473
  phosphorylation and endocytosis 282, 283
  salmeterol interaction with 7TM domain protein of 149–151 (L)
β_3-Adrenoceptor(s) 257–258 (L), 449–454
  agonists and antagonists 71, 74
  cardiac 70, 71–72
  colonic 74
  pharmacological criteria for detection/classification 52–53 (L), 258 (L)
  pharmacological properties 257–258 (L)
  polymorphism, obesity and diabetes and 449–454
β_4-Adrenoceptor(s) (=fourth β-adrenoceptor), cardiac 72–76, 181
  agonists 71, 72, 181
  antagonists 71
β-Adrenoceptor kinase (βARK) 282–283
Adrenocorticotrophic hormone, *see* ACTH
Ω-Agatoxin and P/Q Ca^{2+} channels 365, 366–367
Aging and dehydroepiandrosterone 447–449
Agonists 355–362, 414–417, 468–474
  G protein-coupled receptor and, *see* G protein-coupled receptors
  inverse 358–360, 468–474
    and regulation of receptor number 468–474
  three-state receptor model of action 355–362
AIDS-related dementia and NO 189–190
Airway
  cysteinyl leukotriene receptors 148–149 (L)
  disease (in general) 465–467
    eosinophils and 119–123, 465–466, 467–468
    phosphodiesterase type 4 inhibitors 166, 167
    see also specific diseases
  inflammation 121
    asthma and 288–292, 465, 467
    NF-κB and 46–50
    phosphodiesterase type 4 inhibitors 166
  mucosa, *see* Mucosa
  smooth muscle, asthma and 288–292
  see also Lung; Pulmonary vasculature
Alcohol/ethanol
  craving/dependence 54–59, 229–231
    animal models 55
    management 54–59, 229–231
  tobacco smoke-related cancer and 273
Alcuronium 414–415
Aldosterone secretion by adrenal glomerulosa cells involving T-type Ca^{2+} channels 41
Allergic disease 119–123, 465–467
  airway 119–123, 166, 465–467
  eosinophils and 119–122
  phosphodiesterase type 4 inhibitors 166
  see also specific diseases
Allosteric modulators
  benzodiazepine binding site of $GABA_A$ receptors 425–429
  muscarinic receptors 414–416
α-factor (yeast), G protein-coupled receptor for 283
α1B-subunit of Ca^{2+} channels
  N channels 363
  P/Q channels 365
Alzheimer's disease and dehydroepiandrosterone 447, 448
Amino acids
  analogues, as selective NO synthase inhibitors 205–208
  excitotoxic, *see* Excitotoxicity
4-Aminobenzoic acid (and derivatives) as farnesyltransferase inhibitors 442
γ-Aminobutyric acid, *see* GABA
Amisulpride 98
AMP, cyclic (cAMP), opioid withdrawal and 136, 137, 138
cAMP-elevating agents, phosphodiesterases as, *see* phosphodiesterases
cAMP-responsive element binding protein and memory 130
AMPA receptors 141–142
  amyotrophic lateral sclerosis and 199
Amylin receptor 456–457
Amyotrophic lateral sclerosis 196–203, 330
  animal models 198–199, 330
  genetic factors 196–197
  pathological mechanisms 197–198
  therapies 199–202
Anaesthetics, general, transmitter-gated ion channels and 454–455
Analgesia tests, nociceptin/orphanin FQ in 298
Anandamide, vascular endothelial effects 255
Angiogenesis, receptors induced in 168
Angiotensin (AT_1/AT_2) receptors 375, 376
  nonpeptide antagonists 379–380
    therapeutic potential 382
Angiotensinogen gene, antisense oligonucleotides 13
Anthracyclines 326, 327
Anti-arrhythmics 64 (BR)
  in myocardial ischaemia 224–228, 345 (erratum)

see also specific drugs and arrhythmias
Anti-cancer agents
CA_1A_2X-competitive inhibitors of farnesyltransferase 437–445
camptothecin as 445–446 (BR)
topoisomerase poisons, molecular determinants of DNA sequence specificity 325–327
Anticonvulsant prophylaxis after brain injury 59–62
Antidepressants 35 (L)
nonpeptide neuropeptide receptor antagonists as 381
presynaptic receptor targeting 98
Antidysrhythmics, *see* Anti-arrhythmics
Anti-emesis in cancer therapy, ondansetron in, Mullard Award for scientists responsible for success 306
Anti-epileptic prophylaxis after brain injury 59–62
Antifungals 70
Anti-inflammatory effects of phosphodiesterase 4 inhibitors 164–171
Antimycotics 70
Anti-oestrogens 182
breast cancer 245–251, 345–346 (erratum)
nonsteroidal 247–249
steroidal 249–250
Anti-oxidants, amyotrophic lateral sclerosis 202
Antiparkinsonian drugs, *see* Parkinson's disease
Antipsychotics/neuroleptics 35 (L), 186–188
presynaptic receptor targeting 98
Antisense knockdown, contribution to drug discovery 218
Antisense oligonucleotides
to G proteins in ion channel studies 9–10
in vivo studies with 12–18
clinical pharmacokinetics 14–16
pre-clinical efficacy 12–16
safety and toxicity 16–17
Anxiolytics, nonpeptide neuropeptide receptor antagonists as 381
AP-1, TNF-α/IL-1 and 319–320
Apamin-sensitive SK channel 348
Apoptosis
Bcl-2-related proteins and 51
eosinophil 118
neurotrophins and 336
NO and 189–190
Appetite suppressants and 5-HT receptors 21–25, 191–192 (L)
see also Food
Arachidonic acid metabolites 30
vascular endothelial effects 253–254, 421
L-Arginine, guanidino-substituted analogues, as selective NO synthase inhibitors 205
ARL67516 263–266
Aromatic hydrocarbon receptor induction 176–177
β-Arrestin 282, 283
Arrhythmias, cardiac
drugs treating, *see* Anti-arrhythmics
in myocardial ischaemia 224–228, 345 (erratum)
myocardial reperfusion (post-ischaemia)-induced 242
Arthritis, *see* Rheumatoid arthritis
Aspirin, COX-1 inhibition 32–33
Asthma 46–50, 288–292, 465–467
airway in, *see* Airway
eosinophils and 119–123
mouse models 465–467
NF-κB and 46–50
phosphodiesterase type 4 inhibitors 166
Atopic dermatitis and eosinophils 119
ATP
breakdown, nucleotidases and 263–266
release/metabolism/conversion to ADP 43–50
ATP diphosphorylase, ecto- 390
ATPase, ecto- 390
Autocrine effects of growth factors produced by airway smooth muscle 288–289
Autocrine mediators of leukocyte–endothelium interactions 421–424
Autoimmune mechanisms, amyotrophic lateral sclerosis 197
Autonomic nervous system 259 (BR)
endocrine and, interactions 301 (BR)
Autoreceptor(s)
dopamine D2, and antiparkinsonian drug responses 232–235
presynaptic 95–96
Axons, *see* Growth; Neurones; Neuroregeneration
Azathioprine 3
clinical pharmacology 5–6
transplantation and 7
Azilimide 28–29

B
B-cell leukaemia oncogene-2, *see* Bcl-2
B581 438, 439
B956 439, 440
B1086 439, 440
Baclofen 103
Barium ions and Ca^{2+} channels 368–369
Bcl-2 (and Bcl-2-related proteins) 51
motor neurone disease and 333, 335
Behaviour, adenosine A_{2A} receptor antagonist effects 342–343
Benzodiazepines
as farnesyltransferase inhibitors 441–442
$GABA_A$ receptor binding site for 425–429
β-cell insulin secretion 131
β-subunit of Ca^{2+} channels 39–40
G protein interactions with 10
BIBP3226 379
BK channels 349–350
Blood pressure
α_2-adrenoceptors and 215–216, 219
raised, *see* Hypertension
Bombesin receptor nonpeptide antagonists 380
Bosentan 409, 410
Botulinum neurotoxins 97, 98
Bowel, large, *see* Colon
Bradykinin receptor
induction 175
during inflammation 173–174
nonpeptide antagonists 380
Brain
A currents and voltage-gated K^+ channels 480
α_2-adrenoceptors 215
5-HT_7 receptors 105–106
injury/damage
anticonvulsant prophylaxis 59–62
organophosphorus-induced 183–184
pharmacology 35 (L)
Brain-derived neurotrophic factor in motor neurone disease/amyotrophic lateral sclerosis
adverse effects 336
disease models 331
therapeutic potential 201, 202, 336
Breast cancer 245–251, 345–346 (erratum)
anti-oestrogens, *see* Anti-oestrogens
oestrogen–growth factor cross-talk 245–247
Bristol–Myers Squibb Unrestricted Biomedical Research Grants Programme 151–152
BRL37344 52 (L), 52–53 (L)
Bromocriptine in Parkinson's disease 161
dyskinesias with 162
BSc in pharmacology and fulfilment of needs in first employment 111–116
BZA-2B and BZA-5B 441, 442

C
C-type inactivation of K^+ channels 347
CA_1 cells (hippocampal), T-type Ca^{2+} channels 39
CA_1A_2X-competitive inhibitors of farnesyltransferase 437–445
Cabergoline 157, 159, 160–161, 161–162
dyskinesias with 162
Caenorhabditis elegans egl-36 480–481
Cajal's interstitial cells and GI motor disorders 393–403
Calcineurin 124–134
function 124, 126–133
inhibitors 126
structure and regulation 124–126
Calcitonin gene-related peptide receptor, orphan G protein-coupled receptor functioning as 435
Calcitonin receptors 460, 461
Calcium ion(s)
amyotrophic lateral sclerosis and 199
channels 37–42, 363–371
antagonist, new 37–38
biology 38–39
calcineurin and 124–130, 131
counting 370
G proteins and 8–11
molecular properties 39–40
N-type, *see* N-type Ca^{2+} channels
oxygen-sensitive 406, 407
P/Q 364–365, 366–367
R-type 365–366
T-type, *see* T-type Ca^{2+} channels
K^+ channel activation by 348–350
release mechanism, gating by novel pyridine nucleotide 108–110
Camptothecin 445–446 (BR)
Canada, Institute of Pharmacology at Sherbrooke 65
Cancer
breast, *see* Breast cancer
drugs acting against, *see* Anti-cancer agents
lung 270–275
ondansetron in anti-emesis, Mullard Award for scientists responsible for success 306
tobacco smoke-related 270–275
Cannabinoids, vascular effects 255
Carbenoxolone 273
Carbon monoxide 193–195
endothelial effects 253
guanylate cyclase and 193–195, 488
Carbonyl reduction of NNK in smokers 270–271
by 11β-hydroxysteroid dehydrogenase 271–272
Carcinogens, tobacco smoke 270–275
Cardiotrophin-1 335
Cardiovascular system
α_2-adrenoceptors and 215–216
research grants/awards 151–152
see also Heart
Carotid body, O_2-sensitive ion channels 405, 406, 407
Catecholamine secretion by chromaffin cells, T-type Ca^{2+} channels and 40–41
Catechol-O-methyl transferase inhibitors 157, 162
Cathepsin D and breast cancer 245
Cathepsin G 424
CCK receptor induction 175, 176
CDP840 166, 169
Cell
adhesion molecules, NF-κB and 48, 49
death, *see* Death
growth and proliferation, T-type Ca^{2+} channels and 41–42

Central nervous system
5-HT_7 receptors 105–106
nociceptin/orphanin FQ 295–298
organophosphorus toxicity 183–185
T-type Ca^{2+} channels 39
Cerebral cortex and opiate addiction 77–78 (L)
Cervical ganglion, rat superior, purino-/pyrimidinoceptors 413
CGP12177 as fourth cardiac β-adrenoceptor agonist 72, 73–76, 181
CGS21680 341, 342, 343
CGS26303 412
Charybdotoxin 348, 349
Chemokines/chemotaxins, airway inflammation/asthma and 46, 47, 48, 288, 291
NF-κB and 48, 49
production 288, 291
Chloride ion currents, myocardial ischaemia and 226
p-Chlorophenylalanine (PCPA) and 5-HT 21–22, 22, 191 (L), 192 (L)
m-Chlorophenylpiperazine (mCPP) and 5-HT 23, 191 (L)
Cholecystokinin receptors
induction 175, 176
nonpeptide antagonists 373, 375, 376–377, 377–378, 378–379
therapeutic potential 381, 382
Cholesterol synthesis, postsqualene 67–70
Cholinergic activity, striatal, Parkinson's disease and 340, 341–342
Chromaffin cells, catecholamine secretion by, T-type Ca^{2+} channels and 40–41
Chromanols as I_{minK} channel activators 29
CI1020 410–411
CIFM (farnesyltransferase inhibitor) 438
Cigarette smoke-related cancer 270–275
Ciliary neurotrophic factor in motor neurone disease/amyotrophic lateral sclerosis
in disease models 331
synergy with other neurotrophins 333, 335
therapeutic potential 201, 202, 336
Citrulline analogues as selective NO synthase inhibitors 205–208
Clerocidin 326
Clonidine 218
opioid withdrawal and 138
Cocaine 35 (L)
Cognitive function
dehydroepiandrosterone levels and 447–448
$GABA_B$ receptor ligands as enhancers of 103
Colitis, ulcerative 399
Colon
$β_3$-adrenoceptors 52 (L), 52–53 (L), 74
I_{minK} channel 28
Computers (in teaching/education) 63 (BR)
simulation of laboratory experiments 317
Ω-Conotoxin and N-type Ca^{2+} channels 363, 364, 366–367
Convulsions, *see* Seizures
Copper ions and guanylate cyclase 488
Coronary heart disease and NO 239–241
Cortex, cerebral, opiate addiction and 77–78 (L)
Corticosteroids, NF-κB and asthma and 49–50
Corticotrophin, *see* ACTH
Corticotrophin-releasing hormone receptor, nonpeptide antagonists and their therapeutic potential 380, 381
secretion 91
Courses in pharmacology
degree, and fulfilment of needs in first employment 111–116
in medical schools 314–318
CP77059 166, 167
CP80633 166, 169
CP96345 377
CP99994 374
CREB and memory 130
Crohn's disease 399
CVFM (farnesyltransferase inhibitor) 438
derivatives 439, 440
Cycas circinalis and amyotrophic lateral sclerosis 197
Cyclic nucleotides, *see* ADP ribose, cyclic; AMP, cyclic; GMP, cyclic; Phosphodiesterases
Cyclooxygenases (prostaglandin H_2 synthases) 30–34, 311–313 (L)
COX-1 30–31
effects of drugs on 32
selective inhibitors 32–33
COX-2 30–31
effects of drugs on 32
selective and highly selective inhibitors 33–34, 64 (BR)
nonselective inhibitors 33
Cyclosporin A, calcineurin inhibition 126, 127, 128, 131
Cysteinyl leukotriene receptors 148–149 (L)
Cytokines, airway
inflammation/asthma and 46, 47, 48, 288, 291
production 288, 291
see also specific cytokines
Cytoskeletal abnormalities in amyotrophic lateral sclerosis 197

D
D79N mutant mice 216–217
DATOTOP study in Parkinson's disease 157, 158
Death, cell
NGF promoting 336
NO-induced 189–190
see also Apoptosis; Necrosis
Degree courses in pharmacology and fulfilment of needs in first employment 111–116
Dehydroepiandrosterone 447–449
Dementia, AIDS-related, NO and 189–190
Dendrotoxins 480
L-Deprenyl in Parkinson's disease and its therapy 157–160
Depression (at synapses), long-term, calcineurin and 129–130
Depressive disorders, *see* Antidepressants
Dermatitis, atopic, eosinophils and 119
Desensitization (receptors)
definition 277
G protein-coupled receptors 282, 285
NMDA receptors, calcineurin and 127
Development, nervous system, NO and 189
Dexmedetomidine (DEX) 215, 216, 217, 218
Diabetes
$β_3$-adrenoceptor polymorphism and 449–454
somatostatin analogues in 94
Dihydropyridine and Ca^{2+} channel types 363
Discovery, drug 19–20
G protein-coupled orphan receptors and 430–437
Disulfiram 230, 231
Diverticular disease 399
DNA-sequence specific actions of topoisomerase II poisons 323–329
Dofetilide 227
L-Dopa, *see* Levodopa
Dopamine 338–340
appetite suppressants and 24
opiate addiction and 77–78 (L)
striatonigral neurones regulated by 338–340
transport inhibitors/uptake blockers in Parkinson's disease 233, 309
Dopamine receptor
adenosine A_{2A} receptor antagonist effects 342
agonists in Parkinson's disease 156–162, 232–233, 235, 307–310 (L)
adverse effects 156–157, 162
second generation 158–159
selective 157–160
antagonists in schizophrenia, D4 186–188
Dopaminergic system
antiparkinsonian drug responses of cells in, autoreceptor-mediated 156–162
neuropsychiatric disorders linked to, nonpeptide neuropeptide receptor antagonists with 382
neurotensin and 380–381
Dorsal horn and opioid withdrawal 139, 140
Dorsal root ganglion cells
nociception and 223
T-type Ca^{2+} channels of 366–367
Drugs
addiction, *see* Addiction
discovery, *see* Discovery
prototypes, and their exploitation 259–260 (BR)
see Antidepressants
tobacco smoke-related cancer and 273–274
Drugs and the Brain 35 (BR)
Dyskinesia in Parkinson's disease and its therapy 156–157
Dysrhythmias, cardiac, *see* Anti-arrhythmics; Arrhythmias

E
Ear, inner, I_{minK} channel 28
EB1 receptor induction 175
Ecto-nucleotidases 389–391
soluble 263, 264, 265, 266
EDHFs, *see* Endothelial-derived hyperpolarizing factors
Education/teaching 111–116, 314–318
computers in, *see* Computers
courses, *see* Courses
needs and skills in first employment and value of higher education 111–116
pharmaceutical industry and 19–20
EGF, *see* Epidermal growth factor
Egl-36 480–481
Eicosanoids, vascular endothelial effects 253–254, 421
Elastase 424
Electrical pacemaker activity of interstitial cells of Cajal 393–399, 401–402
Electron microscopy, interstitial cells of Cajal 394
Electrophysiological studies
autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs 232–235
myocardial ischaemia/reperfusion 226–227
Emesis/vomiting
in cancer therapy, ondansetron in management of, Mullard Award for scientists responsible for success 306
phosphodiesterase type 4 inhibitor-induced 168–169
Emopamil binding protein (EBP) 67, 68, 69
Employment of pharmacology graduates, first, higher education and fulfilment of needs in 111–116
Encephalomyelitis, autoimmune, phosphodiesterase 4 inhibitors 165
Endocrine system, *see* Hormones
Endocytosis (of receptors and ligands)
calcineurin and 131
definition 277
G protein-coupled receptors 276–287

Endothelial-derived hyperpolarizing factors 252–256
bioassay 255
mechanisms of action 255–256
Endothelin, pulmonary disease and 409
Endothelin-converting enzyme inhibitors 408, 412
knockout mice 408
Endothelin receptors 408–412
antagonists 408–412
clinical development 408–412
nonpeptide 380, 408–412
ET_B subtypes 409
vascular smooth muscle tone and 409
Endothelium (endogenous mediators) 253–255, 418–425
and hyperpolarization of vascular smooth muscle 253–255
and leukocyte interactions 418–425
Entacapone in Parkinson's disease 157, 162
Enteric nervous system and interstitial cells of Cajal 399–400
Enzymes, leukocyte-derived 424
Enzymology, mathematics in 63 (BR)
Eosinophil(s)
lysis/free granules/eosinophilic diseases 117–123, 465–466, 467–468
phosphodiesterase type 4 inhibitor effects 165
Eosinophil cationic protein 119
Epidermal growth factor
breast cancer and 246
receptor induction 176, 177–178
Epilepsy
absence, $GABA_B$ receptor ligands 103
brain injury causing, anticonvulsant prophylaxis 59–62
Epithelium in asthma 465
Epoxyeicosanoids (including EET), vascular endothelial effects 253–255
Epstein–Barr virus induced receptors 177–178
Ergosterol biosynthesis in yeast 67
Ethanol, *see* Alcohol
Ether à go-go K^+ channel, rat 481
Evans, W. E. on thiopurine methyltransferase 5
Evolution, K^+ channels 347–348
Excitotoxicity (and excitotoxic amino acids) 183–185
amyotrophic lateral sclerosis and 197–198
organophosphorus nerve agents and 183–185
protection from, *see* Neuroprotective agents
Exocytosis and calcineurin 131
Extrapyramidal side-effects, new D4 antagonist with reduced 186–188
Eye, pressure within, α_2-adrenoceptor agonists reducing 219

F

Farnesyltransferase, CA_1A_2X-competitive inhibitors of 437–445
Feeding, *see* Appetite; Food
Females, β_3-adrenoceptors and obesity in 451
D-Fenfluramine and appetite suppression 21–25, 191–192 (L)
Fetal cell transplantation in Parkinson's disease 157, 163
FGF, *see* Fibroblast growth factor
Fibroblast growth factor
breast cancer and 246
myocardial ischaemia and 226
Fibroblast growth factor receptor, basic, induction 174–175, 176
FK506, calcineurin inhibition 126, 127, 128, 129, 131
Floor plate cells, T-type Ca^{2+} channels 40–41
Fluoxetine and appetite suppression 22, 23, 24, 191–192 (L)
Food
constituents, tobacco smoke-related cancer and 273
intake/feeding
5-HT receptors and 21–25, 191–192 (L)
neuropeptide Y and 24
Free radicals, oxygen-derived
amyotrophic lateral sclerosis and 197
endothelial effects 253
myocardial reperfusion and 243
see also Antioxidants
FTI276 441, 442
Fungal infections, new drugs 70
Fungicides 70

G

G protein(s)
Ca^{2+}/K^+ ion channels interacting with 8–11
signal transduction and, *see* Signal transduction
vascular smooth muscle 255
G protein-coupled receptor(s) 43–50, 276–287, 414–417, 456–464
agonists and 414–417, 468–474
identification 468, 470
interactions 414–417, 468–474
inverse 468–474
antagonists, identification 468, 470
conformations, range/multiplicity 415, 416
endocytosis and recycling 276–287
genetic diseases associated with 431, 433
induction 175
during inflammation 173–174, 175
marketed drugs for 432
orphan receptors, *see* Orphan receptors
P2 purinoceptors, pharmacological selectivity 43–50
recombinant vs. natural systems 456–464
G protein-coupled receptor kinase (GRK) 282–283
GABA, Parkinson's disease and adenosine A_{2A} receptor antagonists and release of 338, 339, 341
GABA receptors 260–261 (BR), 425–429
$GABA_A$ 260–261 (BR), 425–429
alcohol-craving and 56
anaesthetic agents and 454–455
benzodiazepine binding site 425–429
$GABA_B$ 260–261 (BR)
metabotropic 103
$GABA_C$ 260–261 (BR)
Gabapentin in amyotrophic lateral sclerosis therapy 201, 202
Gammahydroxybutyrate 230, 231
Ganglion, rat superior cervical, purino-/pyrimidinoceptors 413
Gap junctions, myoendothelial 252
Gastrointestinal tract
β_3-adrenoceptors 52 (L), 52–53 (L)
motor disorders, interstitial cells of Cajal and 393–403
see also specific regions
Gastroparesis 399
Gender, β_3-adrenoceptors and obesity and 451
Gene targeting, α_{2c} adrenoceptors 215–216
General anaesthetics and transmitter-gated ion channels 454–455
Genetic factors
amyotrophic lateral sclerosis 196–197
Parkinson's disease 160–161
Genetic induction of receptors 171–181
Genetic models of amyotrophic lateral sclerosis 198–199
Genetic polymorphism, *see* Polymorphism
Genome, human, 1st annual European meeting 303–306
Glial cell-derived neurotrophic factor in motor neurone disease models 333
Glomerulonephritis, phosphodiesterase type 4 inhibitors 166
Glomerulosa cells, adrenal, aldosterone secretion involving T-type Ca^{2+} channels 41
Glucocorticoids
NF-κB and asthma and 49–50
tobacco smoke carcinogens and 272
Glutamate, presynaptic regulation of release 127–128
Glutamate receptors 141–148
alcohol-craving and 56
calcineurin and 126–127, 127–128
channels in
postsynaptic regulation 126–127
sizes 146–147
inotropic 141–148
unitary 145–146
native occurrence and possible functions 145–146
requirements for formation 145
see also specific receptors
Glycyrretinic acid 273
GMP, cyclic (cGMP), NO and 243
Ca^{2+} and 266–268
Graduates, higher education in pharmacology and fulfilment of needs in first employment 111–116
Grafting, *see* Transplantation
Grants, research, Bristol–Myers Squibb Unrestricted Biomedical Programme 151–152
Growth, cell
neuronal/axonal 40
motor neurone disease and 335
and proliferation, T-type Ca^{2+} channels and 41–42
Growth cone movement, T-type Ca^{2+} channels and 40
Growth factors
airway smooth muscle production 291
autocrine effects 288–289
motor neurone disease therapy, small-molecule 336
oestrogen and, cross-talk in breast cancer 245–247
in Parkinson's disease therapy 309 (L)
Growth hormone, pulsatility, ontogeny 90–91
Growth hormone release inhibiting hormone, *see* Somatostatin
Guam amyotrophic lateral sclerosis 197
Guanidino-substituted analogues of L-arginine as selective NO synthase inhibitors 205
Guanylate cyclase 193–195, 484–491
metalloporphyrins inhibiting 193–195
NO and 243, 484, 486–490
soluble 484–491

H

Haem-binding domain of guanylate cyclase 486–487, 487
Haem oxygenase, CO generation 193–195
Haematopoietic toxicity, thiopurines 7
Hanatoxin and K^+ channels 480
Heart
adenosine and the 236–238
arrhythmias, *see* Arrhythmias
β-adrenoceptors, *see* β-Adrenoceptors
I_{minK} channel 27–28
myocardium, *see* Myocardium
NO and disease of 239–244
T-type Ca^{2+} channels 42
voltage-gated K^+ channels 479–480
see also Cardiovascular system
Hepatitis B virus, duck, antisense oligonucleotide to 13
Heterocyclic compounds as selective NO synthase inhibitors 208–210
Heteropodatoxin and K^+ channels 480
Heteroreceptors, presynaptic 96–97

Hexokinase, nucleotide triphosphate utilization 45
Higher education in pharmacology and fulfilment of needs in first employment 111–116
Hippocampus
T-type Ca^{2+} channels in CA_1 cells 39
voltage-gated K^+ channels in interneurones 479
Hirschprung's disease 398
Hoehn and Yahr disability scale, Parkinson's disease 156, 157
Hormone(s)
autonomic nervous system and, interactions 301 (BR)
receptors, induction 177, 178
see also specific (types of) hormones
Hughes, J. W. (in obituary of H. W. Kosterlitz) 1–2 (O)
Human Genome Europe Meeting, 1st annual 303–306
γ-Hydroxybutyrate 230, 231
11β-Hydroxysteroid dehydrogenase 270–275
physiological role 272
tobacco smoke carcinogens and 270–275
4-Hydroxy-tamoxifen 248, 250
5-Hydroxytryptamine receptors 21–25, 104–107, 191–192 (L)
appetite suppressants and 21–25, 191–192 (L)
5-HT_{2A}, agonists/antagonists 457, 460
5-HT_{2C} 21–25
5-HT_7 104–107
agonists/antagonists 106
Hyperalgesia, nociceptin/orphanin FQ and 298–299
Hyperpolarization of vascular smooth muscle 252–256
Hypertension
α_2-adrenoceptors 215–216, 219
AT_1 receptor nonpeptide antagonists in 382
Hypophagic effects of appetite suppressants 21–23, 191–192 (L)
Hypothalamic–pituitary–adrenocortical axis and neurotensin 381
Hypothalamus
nucleus periventricularis/paraventricularis of, *see* Periventricular nucleus
somatostatin and the 87–89
Hypoxia affecting ion channels 405–408

I

IκB 46, 179
I_{minK} channel 26–29
activators 29
blockers 28–29
I_{SK} (minK) protein 26–29, 350
see also SK channels
ICI 118,551 471
ICI 164,384 249–250
ICI 182,780 249–250
Idoxifene 248–249
Immunohistochemistry
α_2-adrenoceptor 215
interstitial cells of Cajal 394–395
Immunological models of amyotrophic lateral sclerosis 199
Immunophilin ligands, neurotrophic, in Parkinson's disease 309 (L)
Immunosuppression, phosphodiesterase type 4 inhibitor-induced 169
Immunosuppressive drugs
in amyotrophic lateral sclerosis 199, 201, 202
as calcineurin inhibitors 126
Infantile pyloric stenosis 398–399
Infectious agents, receptors induced by 177–178
Inflammation
airway, *see* Airway
phosphodiesterase 4 inhibitors in 164–171
receptor induction during 173–174
Inflammatory bowel disease 399
Injury (tissue)
brain, anticonvulsant prophylaxis following 59–62
ischaemia–reperfusion, *see* Ischaemia–reperfusion injury
receptor induction during 174–177
Inotropic glutamate receptors 141–148
Institute of Pharmacology at Sherbrooke (Canada) 65
Insulin
breast cancer and 246
secretion by pancreatic β cells 131
Insulin-like growth factor (IGF) and IGF-binding protein, airway smooth muscle production 289
Insulin-like growth factor-I (IGF-I) in amyotrophic lateral sclerosis therapy 201, 202
breast cancer and 246, 247, 248, 249
Integrins and airway inflammation/asthma 289–290
Interleukin-1, signal transduction and 319–322
Interleukin-1 receptor gene, antisense oligonucleotide to 13
Interleukin-1β, airway smooth muscle production 289
Interleukin-2 receptor induction 172–173
Internalization of receptors and ligands
definition 277
measurement 276–279
Interneurones, hippocampal, voltage-gated K^+ channels 479
Interstitial cells of Cajal and GI motor disorders 393–403
Intestine
large, *see* Colon
motor disorders, interstitial cells of Cajal and 393–403
Intraocular pressure reduction, α_2-adrenoceptor agonists 219
Inward rectifier channels 350
Ion channels
bcl-2-related proteins in 51
calcineurin and 124–134
in interstitial cells of Cajal 400–401
ligand-gated, *see* Ligand-gated ion channels
oxygen-sensitive 405–408
voltage-gated, *see* Voltage-gated/dependent ion channels
see also specific channels
Ischaemia, myocardial 224–228, 345 (erratum)
Ischaemia–reperfusion injury
myocardial (myocardial stunning) 167, 241–242, 243
arrhythmias following 241
oxyradicals and 243
phosphodiesterase type 4 inhibitors and 167
Ischaemia–reperfusion injury, myocardial (myocardial stunning), NO and 241–242
Isocortex and opiate addiction 77–78 (L)
Isoliquiritigenin and guanylate cyclase 490

K

Kainate receptors 141–143
amyotrophic lateral sclerosis and 199
KF17837 341, 343
Kidney
cyclooxygenase activity 31
transplantation, azathioprine and 7
Kit (and GI motor disorders and the interstitial cells of Cajal) 400–401
immunohistochemistry 394–395
receptor 397
Knockdown, antisense, contribution to drug discovery 218
Knockout mutants (usually mice) 218
α_2-adrenoceptor genes 215–216
contribution to drug research 218
cyclooxygenase-2 312
endothelin receptor 408–409
K^+ channel 350
as motor neurone disease models 330
Kosterlitz, Hans Walter 1–2 (O)
KvLQT1 26–29, 350

L

L-type Ca^{2+} channels
cardiac 42
G proteins and 9
L-745,870 186–188
L745631 441
Lathyrism 197–198
L-Dopa, *see* Levodopa
Leaders in drug discovery programmes 19–20
Learning, nociceptin/orphanin FQ and 299–300
Leukaemia, acute lymphoblastic, 6-mercaptopurine in 5, 6–7, 7
Leukaemia inhibitory factor, motoneurones and 334–335
Leukocyte–endothelium interactions, endogenous mediators inhibiting 418–425
Leukotriene receptors 148–149 (L)
Levodopa (L-Dopa) in Parkinson's disease 156–157, 161, 162, 232–233
adverse effects 156–157, 162
with other drugs 233, 235
Ligand(s)
$GABA_B$ receptor, absence epilepsy/spasticity/cognitive function and 103
immunophilin, neurotrophic, in Parkinson's disease 309 (L)
internalization, *see* Internalization
for orphan opioid receptor 293–300
Ligand-gated ion channels
calcineurin and 130
transmitter-gated ion channels, general anaesthetics and 454–455
Limbic dopamine system, opiate addiction and 77–78 (L)
Lipocortin 1 and leukocyte–endothelium interactions 421–424
Lipoxins and endothelial–leukocyte interactions 421
Lisuride in Parkinson's disease 161
Lithium in alcohol dependence 230, 231
Locomotor impairment, nociceptin/orphanin FQ-induced 299
Locus coeruleus and opioid withdrawal 134–140
Long QT syndrome 29, 348
Long-term depression, calcineurin and 129–130
Long-term potentiation, calcineurin and 129
LSD 35 (L)
LU135252 410
Lung disease
endothelin and 409
malignant, tobacco smoke-related 270–275
see also Airway; Pulmonary vasculature
LY83583 and guanylate cyclase 489
Lymphoblastic leukaemia, acute, 6-mercaptopurine in 5, 6–7, 7
Lysergic acid diethylamide 35 (L)

M

M current 131
Malignant tumours, *see* Cancer

Managers in drug discovery 19–20
MAP kinase kinase kinases 319–322
Mathematics in biomedical sciences 63 (BR)
MBS185878 and MBS186511 443
Medical schools, pharmacology courses in 314–318
Meloxicam, COX-2 inhibition 33
Memantine 185
Memory
  calcineurin and 130
  dehydroepiandrosterone and 447–448
6-Mercaptopurine 3
  clinical pharmacology 5–6
  metabolism 3, 4, 7
    non-genetic factors influencing 6
  therapeutic uses 6–7
  toxicity 7
Mesolimbic dopamine system, opiate addiction and 77–78 (L)
Metabolic disturbances, phosphodiesterase type 4 inhibitor-induced 169
Metabolic research, grants/awards 151–152
Metabotropic $GABA_B$ receptors 103
Metalloporphyrins and their inhibitors in CO research 193–195
Methods in Neurosciences, NO synthase characterisation and functional analysis 100 (BR)
β-Methylamino-L-alanine 197
Methylene blue and guanylate cyclase 489
[4-(Methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) 270–275
S-Methylthiocitrulline as selective NO synthase inhibitor 205–208
Mibefradil 37–38
Mice
  as asthma models 465–467
  mutants
    knockout, *see* Knockout mutants
    as models of motor neurone disease 330–333
    see also specific mutants
  transgenic, *see* Transgenic animals
Migraine, sumatriptan in, Royal Society Mullard Award for scientists responsible for success 306
MinK (I_{sK}) protein 26–29, 350
Mirtazepine 98
Mitogen-activated protein kinase kinase kinases 319–322
Monoamine oxidase inhibitors in Parkinson's disease 157–160, 233–235
Mood-modifying drugs 35 (L)
Morphine (opiate) addiction 77–78 (L)
Motoneurones
  in amyotrophic lateral sclerosis 198–199
  subpopulations, evidence for 333–334
Motor neurone disease 196–203, 330–337
  neurotrophic factors and bcl-2 effects in models of 331–332
Motor problems (generally)
  dopamine D4 receptor antagonist with reduced 186–188
  gastrointestinal, interstitial cells of Cajal and 393–403
  in Parkinson's disease and its therapy 156–157
Mouse, *see* Mice
MPTP-induced parkinsonism 158–159, 160
Mucosa, airway
  in asthma 465–467
  eosinophils 120, 121, 465–466, 466–467
    increased (eosinophilia) 117
Multiple sclerosis models, phosphodiesterase 4 inhibitors, in 165, 167
Muscarinic K^+ channels, G proteins and 8
Muscarinic receptors 414–416
  allosteric modulators binding to 414–416
  phosphorylation and endocytosis 283
Muscle, smooth, *see* Smooth muscle
c-Myb gene, antisense oligonucleotide to 13
c-Myc gene, antisense oligonucleotide to 13
Mycotic infections, new drugs 70
Myocardium
  infarction, NO and 241
  ischaemia 224–228, 345 (erratum)
    and reperfusion, *see* Ischaemia–reperfusion
  ventricular, adenosine and 236–238
Myocytes
  Ca^{2+} channels 42
  cardiac, swelling in myocardial ischaemia 224–228, 345 (erratum)
Myoendothelial gap junctions 252

N
N-type Ca^{2+} channels 363–364
  Ω-conotoxin and 363, 364, 366–367
  G proteins and 9, 10
N-type inactivation of K^+ channels 347, 481–482
N-0923 in Parkinson's disease 157
NAADP, Ca^{2+} release mechanism gated by 108–110
Nabumetone 311 (L), 312 (L)
Naltrexone 56–58, 229–231
L-NAME
  and myocardial infarction 241
  and myocardial stunning 242
Necrosis, eosinophil 118
Neocortex and opiate addiction 77–78 (L)
Neoplasms, *see* Tumours
Neovascularization, receptors induced during 168
Nerve agents, organophosphorus, central poisoning by 183–185
Nerve growth factor
  adverse effects 336
  receptor induction 175–176, 177
Nervous system
  autonomic, *see* Autonomic nervous system
  central, *see* Central nervous system
  enteric, and interstitial cells of Cajal 399–400
  NO in development of 189
Neurobiology (in obituary of H. W. Kosterlitz) 1–2 (O)
Neurodegenerative diseases, *see specific diseases*
Neuroendocrine system and somatostatin 87–95
Neurofilament abnormalities in motor neurone disease/amyotrophic lateral sclerosis 197
  in transgenic mice 330–331
Neurokinins A and B 351–355
Neurolathyrism 197–198
Neuroleptics, *see* Antipsychotics
Neuronal NO synthase, selective inhibitors 204–211
Neurones
  excitability, calcineurin and 126–131
  growth and regeneration, *see* Growth; Growth cone; Neuroregeneration
  motor, *see* Motoneurones; Motor neurone disease
  nucleotidases released from and ATP metabolism of 164, 263
  in Parkinson's disease 338–340
  rhythmic activity, T-type Ca^{2+} channels and 41
Neuropeptide(s) 372–386
  gene expression regulated in striatal neurones 341
  receptors, nonpeptide antagonists 372–386
    side-effects 382
    therapeutic potential 381–382
  somatostatin secretion and the role of 87–89
Neuropeptide Y
  feeding and 24
  receptor, nonpeptide antagonists 378–379
Neuroprotective agents (including anti-excitotoxic agents)
  in amyotrophic lateral sclerosis 201, 202
  in organophosphorus poisoning 185
  in Parkinson's disease 157–160
Neuropsychiatric disorders linked to dopaminergic system, nonpeptide neuropeptide receptor antagonists with 382
Neuroregeneration
  bcl-2-related proteins and 51, 335
  motor neurone disease and 335
Neuroscience research, Bristol–Myers Squibb award in 151
Neurotensin 380–381
  receptor antagonists, nonpeptide 376, 380–381
Neurotoxicity (implying CNS toxicity)
  of excitotoxic amino acids, *see* Excitotoxicity
  organophosphorus nerve agents 183–185
Neurotransmitters
  calcineurin regulating release of 133
  ion channels gated by, general anaesthetics and 454–455
  nucleotidases (soluble) and inactivation of 263–266
  presynaptic receptors modulating release 96, 97–98
  somatostatin secretion and 87–89
  see also specific transmitters
Neurotrophic factors in motor neurone disease/amyotrophic lateral sclerosis
  adverse effects 336
  in disease models 330–331
  synergistic effects 333
  therapeutic potential 199–202, 335–336
Neurotrophic immunophilin ligands in Parkinson's disease 309 (L)
Neutrophils
  endothelial interactions with, endogenous mediators inhibiting 418–425
  phosphodiesterase type 4 inhibitor effects 165
NF-κB 46–50, 179, 319–320
  asthma and 46–50
  gene, antisense oligonucleotide to 13, 16
  inhibitors 50
  TNF-α/IL-1 and 319–320
NGF receptor induction 175–176, 177
Nickel ions blocking T-type Ca^{2+} channels 37
Nicotinic acetylcholine receptor agonists in Parkinson's disease 308 (L)
Nicotinic acid adenine dinucleotide, Ca^{2+} release mechanism gated by 108–110
Nigral cell degeneration, adenosine A_{2A} receptor antagonists reducing effects of 338–344
Nitric oxide (NO) 204–211, 239–244
  airway smooth muscle production 290
  apoptosis and 189–190
  Ca^{2+} and, cross-talk 266–269
  cGMP and, *see* GMP, cyclic
  endothelial effects 253, 420
  guanylate cyclase and 243, 484, 486–490
  heart disease and 239–244
  interstitial cells of Cajal and 400
Nitric oxide synthase (NOS) 204–211
  calcineurin and 130
  characterisation and functional analysis 100 (BR)
  inhibitors 204–211, 239–244
    in heart disease 239–244
    of neuronal NOS, selective inhibitors 204–211
7-Nitroindazole as selective NO synthase inhibitor 208–210
Nitrosamines, tobacco-specific 270–275
NK_1 receptors 175, 223, 351–355

dual nature 351–355
in inflammation 174
in injury 176
on interstitial cells of Cajal 400
nonpeptide antagonists 374, 377
NK_2 receptors 351
nonpeptide antagonists 374
NK_3 receptors 351
nonpeptide antagonists 374
NMDA receptors 141–148
alcohol-craving and 56
antagonists, in organophosphorus poisoning 185
calcineurin and 126–127, 128–129
nociception and 223–224, 345 (erratum)
organophosphorus toxicity and 183, 184–185
NO, *see* Nitric oxide; Nitric oxide synthase
Nociceptin 293–300
Nociception 223–224, 345 (erratum)
Nociceptive threshold, nociceptin/orphanin FQ in tests of 298
Non-insulin dependent diabetes and β_3-adrenoceptors 449–454
Nonsteroidal anti-inflammatory drugs, classification by cyclooxygenase isoenzyme inhibition, *see* Cyclooxygenases
Nonsteroidal anti-oestrogens 247–249
NS-2214 309 (L)
NSAIDs, classification by cyclooxygenase isoenzyme inhibition, *see* Cyclooxygenases
Nuclear factor-κB, *see* NF-κB
Nuclear hormone receptors, *see* Sex steroids
Nucleobase transport processes 391
Nucleoside(s), transport processes 391
Nucleoside diphosphokinase 43–44
Nucleotidases
ecto- 389–391
soluble 263–266
Nucleotides
adenine, release/metabolism/interconversion 43–50
uridine, *see* Uridine nucleotides
Nucleus paragigantocellularis and opioid withdrawal 139, 140
Nucleus periventricularis/paraventricularis, *see* Periventricular nucleus
Null mutants, *see* Knockout mutants

O

Obesity and β_3-adrenoceptor polymorphism 449–454
Ocular pressure, α_2-adrenoceptor agonists reducing 219
ODQ and guanylate cyclase 489
Oedema, airway, in asthma 466
Oestrogens 182 (BR)
cancer and
breast, cross-talk between growth factor and oestrogens 245–247
tobacco smoke-related 272
receptor 182 (BR)
induction 177, 178
Oligonucleotides, antisense, *see* Antisense oligonucleotides
Ondansetron, Royal Society Mullard Award for scientists responsible for success 306
Opiates/opioids 134–140, 172–173, 293–300
addiction 77–78 (L)
endogenous, in obituary of H. W. Kosterlitz 1 (O)
receptors 172–173, 293–300
nonpeptide antagonists 380
orphan 293–300
tolerance, mechanisms 172–173
withdrawal 134–140
Organophosphorus nerve agents central poisoning 183–185
Orphan receptors 104–107, 293–300, 430–437
drug discovery and the importance of 430–437
5-HT_7 receptors 104–107
induction 175
opioid receptors (nociceptin) 293–300
Orphanin FQ 293–300
β-Oxaloamino-L-alanine 197–198
Oxidative stress and amyotrophic lateral sclerosis 197
see also free radicals
Oxygen-sensitive ion channels 405–408

P

P currents and P-type Ca^{2+} channels 364–365, 366–367
P1 purinoceptors, *see* Adenosine
P1/2 purinoceptors, *see* Purinoceptors
P2 receptors (for purines and pyrimidines) 43–50, 79–81, 413
G protein-coupled, pharmacological selectivity 43–50
nomenclature 79–81
P2X 79, 80
P2Y 81, 83–86, 387
pyrimidine-sensitive 83–86
p53 gene, antisense oligonucleotides 15
Pacemaker activity of interstitial cells of Cajal 393–399, 401–402
Pain, *see* Analgesia; Hyperalgesia; Nociception
Pancreatic β cell insulin secretion 131
Pancreatic polypeptide 378
Paracrine mediators of leukocyte–endothelium interactions 418–421
Parasites and eosinophils 119, 121
Parkinson's disease 156–163, 232–235, 307–310 (L)
aetiology 160–161
drug therapy 156–162, 167, 232–235, 307–310 (L), 338–344
adverse effects 156–157, 161
novel/alternative 157, 162, 307–310 (L), 338–344
non-drug therapy 157, 163
PDGF, *see* Platelet-derived growth factor
Peptide receptors, endocytosis 276
see also Neuropeptides
Peptide YY 378
Pergolide in Parkinson's disease 161
Periaqueductal grey and opioid withdrawal 134–140
Peripheral 5-HT_7 receptors 106–107
Periventricular nucleus (PeVN; PVN), somatostatin neurones 87, 89, 90, 91
Pharmaceutical industry, drug discovery and management 19–20
Pharmacology
defining 153–155
education, *see* Education
Pharmacology: A Clinical Core Text for Integrated Curricula with Self-Assessment 63–64 (BR)
Pharmacophore, drug, topoisomerase II poisons and 325–326
Phenytoin in prevention of epilepsy following brain injury 61
Phosphodiesterases (PDE) 164–171
other types 164
type 4, inhibitors of 164–171
adverse effects 168–169
Phosphoprotein phosphatase, calcineurin as 124–134
Phosphorylation, G protein-coupled receptor 282–283
Physical chemistry, mathematics in 63 (BR)
Pindolol as fourth cardiac β-adrenoceptor agonist 72, 72–73
Pituitary tumours 92, 93, 131
see also Hypothalamic–pituitary–adrenocortical axis
Plasma exudation in asthma 466, 467
Platelet(s), cyclooxygenase-1 in 31
Platelet-derived growth factor
BB isoform, airway smooth muscle production 289
breast cancer and 246
receptor induction 176
Pneumonia, chronic eosinophilic 119
Poisoning, *see* Toxicity
Polymorphism, genetic β_3-adrenoceptor
obesity and diabetes and 449–454
thiopurine methyltransferase 3–4
Polymorphonuclear leukocyte–endothelium interactions, endogenous mediators inhibiting 418–425
Postsynaptic regulation of glutamate receptor channels 126–127
Potassium ion channels 8–9, 26–29, 347–350, 474–483
Ca^{2+}-activated 348–349
in disease 348
evolution 347–348
G proteins and 8–9
oxygen-sensitive 405–406
vascular smooth muscle 255
voltage-dependent, *see* Voltage-gated/ion channels
Potassium ion currents, myocardial ischaemia and 226
Potentiation, long-term, calcineurin and 129
Pramipexole 157, 159, 161
Preproenkephalin, striatal gene expression 341
Preprotachykinin, striatal gene expression 341
Prescribing, irrational 314
Presynaptic proteins 97–98
Presynaptic receptors 95–99
as therapeutic targets 98
Presynaptic regulation of glutamate release 127–128
Progesterone and progestins 182 (BR)
receptors 182 (BR)
antisense oligonucleotide to 12, 13
induction 177, 178
tobacco smoke carcinogens and 273
Prostacyclin, vascular endothelial effects 253, 421
Prostaglandin
airway smooth muscle 290
synthesis 30
Prostaglandin H_2 synthase, *see* Cyclooxygenase
Protein(s), presynaptic 97–98
Protein inhibitor of NO synthase, endogenous 210
Protein kinase 1, cGMP-dependent, NO and Ca^{2+} and 267–268
Protein kinase A gene, antisense oligonucleotides 13
Protein kinase C gene, antisense oligonucleotides 12, 13
Pseudo-obstruction, intestinal 399
Pseudosymmetric of channel agonist and channel modulatory sites 425–429
Psychoactive drugs 35 (L)
nonpeptide neuropeptide receptor antagonists as 381–382
Pulmonary vasculature endothelin and disorders of 409
smooth muscle, oxygen-sensitive ion channels 405, 406, 407
see also Lung disease
Purine metabolism 7
see also specific purines
Purinergic neurotransmission, ATPases and 263
Purinoceptors (P) 43–50, 79–86, 338–344

P1, *see* Adenosine receptors
P2, *see* P2 receptors
Purkinje cells/fibres
adenosine and 236
Ca^{2+} currents and 365–366
Pyloric stenosis, infantile 398–399
Pyridine nucleotide, novel, Ca^{2+} release mechanism gated by 108–110
Pyrimidine metabolism/transport 387–391
Pyrimidinoceptors 83–86, 387, 413–414
P2, *see* P2 receptors

Q
Q-type Ca^{2+} channels 365
QT interval, long 29, 348

R
R currents and R-type Ca^{2+} channels 365–366
Raf, receptor induction and 179
c-Raf-1 kinase C gene, antisense oligonucleotide to 12, 13
Ras
CA_1A_2X-competitive inhibitors of farnesyltransferase and 437–445
receptor induction and 179
Rat ether à go-go K^+ channel 481
Raynaud's disease, α_{2B}-adrenoceptor antagonists 219
Receptors
agonist action and the three-state model 355–362
desensitization, *see* Desensitization
endocytosis, *see* Endocytosis
G protein-coupled, *see* G protein-coupled receptors
induction 171–181
mechanisms 179–180
internalization, *see* Internalization
in interstitial cells of Cajal 400–401
inverse agonists and regulation of number of 468–474
presynaptic, *see* Presynaptic receptors
signal transduction, *see* Signal transduction
see also Autoreceptors; Heteroreceptors *and specific receptors*
Redox modulation of O_2-sensitive ion channels 405
Renal tissue, *see* Kidney
Research, Bristol–Myers Squibb Unrestricted Biomedical Grants Programme 151–152
Resensitization, G protein-coupled receptors 285
Respiratory distress syndrome, acute, phosphodiesterase type 4 inhibitors 167
Reticuloendothelial system, antisense oligonucleotide studies 12
Retinal axon regrowth, bcl-2-related proteins and 51
Reverse molecular pharmacology for orphan G protein-coupled receptors 433–434
Reward, nociceptin/orphanin FQ and 299
Rheumatoid arthritis
phosphodiesterase type 4 inhibitors 166
purine metabolism and 7
Rhinitis and eosinophils 120, 121
Rhythmic activity in neuronal structures, T-type Ca^{2+} channels and 41
Riluzole in amyotrophic lateral sclerosis therapy 201, 202
Rolipram 165–169
Ropinirole 157, 158, 160, 162
dyskinesias 162
Royal Society Mullard Award 306
RP67580 374, 377
RP73401 166, 169
RSD1000 series 225, 227
Ryanodine receptors and Ca^{2+} homeostasis 267–268

S
Saccharomyces cerevisiae-based screen for identifying orphan G protein-coupled receptor agonists 436
Salicylate, COX-1 inhibition 33, 312 (L), 313 (L)
Salmeterol interaction with β_2-adrenoceptor protein 149–151 (L)
SB207499 169
SCH44342 442
Schizophrenia, drugs, *see* Antipsychotics
Scientists in drug discovery 19–20
Scorpion toxin and K^+ channels 480
Second messenger systems, *see* Signal transduction
Seizures/convulsions
absence, $GABA_B$ receptor ligands 103
brain injury causing, drug prophylaxis 59–62
organophosphorus-induced 183–184
Selegiline in Parkinson's disease and its therapy 157–160
Septic shock, phosphodiesterase type 4 inhibitors 167
Septide and septide-like ligands 352–354
Serine/threonine protein phosphatase, calcineurin as 124–134
Serotonin receptors, *see* 5-Hydroxytryptamine receptors
Sex (gender), β_3-adrenoceptors and obesity and 451
Sex steroids 182 (BR)
analogues/antagonists, *see* Anti-oestrogens
receptors (nuclear) 182 (BR)
antisense oligonucleotide to 12, 13
induction 177, 178
tobacco smoke carcinogens and 272
Sexual dimorphism, somatostatin and 90–91
Shaker K^+ channels 347
Sherbrooke (Canada), Institute of Pharmacology at 65
Shock, septic, phosphodiesterase type 4 inhibitors 167
SIB1508Y 308 (L)
Sigma receptors 67–70
Signal transduction (and second messenger systems) 446 (BR)
G proteins and 286, 446 (BR)
ion channels and 8–11
guanylate cyclase and 484–491
T-type Ca^{2+} channels and 42
TNF-α/IL-1 and 319–322
SK channels 348–349
see also I_{SK} protein
Slow waves and pacemaker activity of interstitial cells of Cajal 393–399, 401–402
Smoking and cancer 270–275
Smooth muscle
airway, asthma and 288–292
gastrointestinal, interstitial cells of Cajal and 396, 402
vascular, *see* Vascular smooth muscle
SNAP-25 97
Sodium ion channels, voltage-dependent 131
Somatostatin 87–95
clinical exploitation of neuroendocrine role 92–94
exocytosis by pancreatic β cells induced by 132
Sotalol, harmful effects of d-enantiomer 306–307
Spasticity, $GABA_B$ receptor ligands 103
Spatial learning, nociceptin/orphanin FQ and 299–300
Spider toxins and K^+ channels 480
Spinal cord and nociception 223–224, 345 (erratum)
Squalene, sterol synthesis after 67–70
SR48692 376, 380–381
SR48968 374
SR57746A in amyotrophic lateral sclerosis 202
SR59230A 52 (L), 257 (L)
SR141716A, vascular effects 255
Statistics in pharmacology 63 (BR)
Ste2p (G protein coupled receptor for α-factor) 283
Steel factor and interstitial cells of Cajal 401
Steroid(s)
adrenocortical, *see* Glucocorticoids
sex, *see* Sex steroids
tobacco smoke carcinogens and 272–273
Steroidal anti-oestrogens 249–250
Sterol synthesis, postsqualene 67–70
Stimulants 35 (L)
Streptonigrin 325
Stress-related disorders, nonpeptide neuropeptide receptor antagonists 381
Striatum, adenosine A_{2A} receptor and Parkinson's disease and 338–344
Substance P 352–354
nociception and 223
Sumatriptan, Royal Society Mullard Award for scientists responsible for success 306
SWORD study 306
Sympathetic nerves, soluble nucleotidase released from 263–264
Synapse 124–134
calcineurin regulation of function 124–134
plasticity 128–130
Synaptobrevin 97
Synaptosome associated protein of 25 kDa 97
Syntaxin 97

T
T cells and airway inflammation/asthma 289–290
T-type Ca^{2+} channels, low-voltage-activated 37–42, 366–370
biology 38–39
biophysical and pharmacological properties 37–38
function and regulation 40–41
molecular properties 39–40
Tachykinins
nociception and 223
receptors, NK, *see* NK
see also specific tachykinins
TAK044 409–410
Tamoxifen 247–248
Tarantula toxin and K^+ channels 480
Teaching, *see* Education
TGFs and breast cancer 245
Thalamocortical projections, voltage-gated K^+ channels 479
6-Thioguanine 3
clinical pharmacology 5–6
metabolism 3, 4
therapeutic uses 6–7
Thioguanine nucleotides (TGN) 3, 5, 6
toxicity 7
Thiopurine(s) 3–7
clinical pharmacology 5–6
metabolism 3, 4, 7
non-genetic factors influencing 6
therapeutic uses 6–7
toxicity 7
Thiopurine methyltransferase 3
gene
cloning 3
polymorphism 3–4
intraethnic differences in activity 6
Thrombin and endothelial–leukocyte interactions 421
Tin metalloporphyrins in CO research 193–195
TNF-α, *see* Tumour necrosis factor α
Tobacco smoke-related cancer 270–275
Tolcapone in Parkinson's disease 157

Topoisomerase II poisons, DNA-sequence specific actions 323–329
Toremifene 248
Torsades de pointes and adenosine 236
Toxicity
antisense oligonucleotides 16–17
CNS, *see* Neurotoxicity
haematopoietic, thiopurines 7
see also specific toxins
Transcription factors, TNF-α/IL-1 and 319–320
Transcriptional induction of receptors 171–181
Transforming growth factors and breast cancer 245
Transgenic animals (mainly mice)
drug discovery and 218
as motor neurone disease/amyotrophic lateral sclerosis models 199, 330
Transmitters, *see* Neurotransmitters
Transplantation/grafting
fetal cell, in Parkinson's disease 157, 163
thiopurine metabolism and 7
Trimethylphenylfluoroimidazole as selective NO synthase inhibitor 208–210
Tumour(s)
breast, *see* Breast cancer
malignant, *see* Cancer
pituitary 92, 93, 131
Tumour necrosis factor α, signal transduction and 319–322
Tumour necrosis factor α-stimulated gene 6 and endothelial–leukocyte interactions 421
Tutorials for Biomedical Sciences 63 (BR)

U
UDP, *see* Uridine nucleotides
UK14304 216, 219
Ulcerative colitis 399
Uncoupling protein (UCP) and obesity 452–453
Unified Parkinson Disability Rating Scale 159, 161, 162
Unit for Research on Addictive Drugs 1 (O)
Uridine nucleotides (UDP; UTP) 43–50, 83–86, 387–392
receptors 83–86, 413
release/metabolism/interconversion 43–50
Uridine phosphorylase 389
UTP, *see* Uridine nucleotides

V
VAMP II 97–98
Vas deferens, effects of sympathetic nerve stimulation 263, 264, 265
Vascular endothelium, *see* Endothelium
Vascular smooth muscle
hyperpolarization of 252–256
oxygen-sensitive ion channels 405, 406, 407
pharmacology 100–101 (BR)
tone, endothelin receptors and 409
Vasoactive intestinal polypeptide receptors
on interstitial cells of Cajal 400
zinc metalloporphyrins and 194
Vasopressin receptor gene, antisense oligonucleotides 13
Ventricular myocardium and adenosine 236–238
Vesicle-associated membrane protein II 97–98
VIP receptors, *see* Vasoactive intestinal polypeptide receptors
Viruses, receptors induced by 177–178
Voltage-gated/dependent ion channels
Ca^{2+} channels 363–371
G proteins and 9–10
T-type, *see* T-type Ca^{2+} channels
calcineurin and 130–131
K^+ channel 131, 347, 474–483
inactivation systems 347, 481–482
modulation by accessory subunits 474–478
slowly activating (I_{minK}) 26–29
subtype localization and identification 478–480
toxins as tools for studying 480
Na^+ channels 131
Vomiting, *see* Emesis

W
W mutant mouse 396, 398
Weinshilboum, J. on thiopurine methyltransferase 5
Women, β_3-adrenoceptors and obesity in 451

X
Xenopus NMDA receptors 143–145

Y
YC-1 and guanylate cyclase 489–490
Yeast, ergosterol biosynthesis 67
Yeast-based screen for identifying orphan G protein-coupled receptor agonists 436

Z
ZD1611 411–412
Zinc metalloporphyrins in CO research 193–195
Zolpidem 426–427

Books Reviewed Index

B

Broadley, K., *Autonomic Pharmacology* 259

C

Challiss, R. A. J., ed., *Receptor Signal Transduction Protocols* 446

E

Enna, S. J., ed., *The GABA Receptors* (2nd Edn) 260

G

Garland, C. J. and Angus, J. A., eds, *Pharmacology of Vascular Smooth Muscle* 100

M

Maines, M. D., ed., *Nitric Oxide Synthase: Characterization and Functional Analysis* 100

P

Pantazis, P., Giovanella, B. C. and Rothenberg, M. L., eds, *The Camptothecins: from Discovery to the Patient* 445

Pavlik, E. J., ed., *Estrogens, Progestins and their Antagonists* (Vols 1 and 2) 182

Pidgeon, C., ed., *Tutorials for the Biomedical Sciences* 63

S

Sneader, W., *Drug Prototypes and their Exploitation* 259

Snyder, S. H., *Drugs and the Brain* 35

U

Unsiker, K., ed., *Autonomic–Endocrine Interactions* 301

W

Winstanley, P. and Walley, T., *Pharmacology. A Clinical Core Text for Integrated Curricula with Self-Assessment* 63

TECHNICAL TIPS ONLINE

Bags of free tips for molecular biologists

A unique online journal of peer-reviewed molecular biology techniques articles

http://www.elsevier.com/locate/tto
in Europe http://www.elsevier.nl/locate/tto

KEY FEATURES

- free to use
- coverage of: PCR, gene expression, cloning & sequencing, and much more
- discussion/feedback for all articles
- rapid publication
- EMBASE/MEDLINE abstracts
- information about products cited in articles
- new product information

http://www.elsevier.com/locate/tto
in Europe http://www.elsevier.nl/locate/tto





ELSEVIER TRENDS JOURNALS